These findings provide a new molecular perspective on the immunosuppressive effect of RFA therapy, suggesting the possibility of enhancing therapeutic efficiency and reducing tumor recurrence through the combined use of NK cell activators (such as anti‐KIR and SLAMF7‐targeting antibodies) and PD‐L1 monoclonal antibodies (e.g., durvalumab) during RFA therapy.234, 235, 236. This evidence concerns the gene CD274 and neoplasm.